Dalantercept
drugOn this page
Also known as ACE-041
Summary
Dalantercept (CHEMBL2109662) is a phase-3 clinical-stage protein; indicated across 5 conditions including colorectal neoplasm and head and neck squamous cell carcinoma.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Protein
- Indications: 5 conditions
- Clinical trials: 5
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL2109662 |
| Name | Dalantercept |
| Type | Protein |
| Max phase | 3 |
Also known as: ACE-041, Dalantercept, DALANTERCEPT
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
5 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| colorectal neoplasm | 3 | MONDO:0005335 | EFO:0004142 |
| head and neck squamous cell carcinoma | 2 | MONDO:0010150 | EFO:0000181 |
| renal cell carcinoma | 2 | MONDO:0005086 | EFO:0000681 |
| plasma cell myeloma | 1 | MONDO:0009693 | EFO:0001378 |
| hepatocellular carcinoma | 1 | MONDO:0007256 | EFO:0000182 |
Clinical trials
Total trials: 5.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE2 | 4 |
| PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT01458392 | PHASE2 | COMPLETED | Study of Dalantercept in Patients With Squamous Cell Carcinoma of the Head and Neck |
| NCT01642082 | PHASE2 | COMPLETED | Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer |
| NCT01720173 | PHASE2 | COMPLETED | Dalantercept in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer |
| NCT01727336 | PHASE2 | TERMINATED | Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma |
| NCT00996957 | PHASE1 | COMPLETED | Study of ACE-041 in Patients With Advanced Solid Tumors or Relapsed/Refractory Multiple Myeloma |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Diseases: colorectal neoplasm